Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms
Sandra E. Kurtin, PhDc, ANP-C, AOCN®
Posted: 7/16/2018
Expires: 7/16/2019
Credits/Contact Hours: 1.0
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Instructions for Earning CE credit
If you would like to earn credit, you must take the pre-test first by clicking here
Review CE information and Begin Pre-test
Quick Tips
What are the germline mutations in patients predisposed to MPN/MDS?
What should I know about the JAK-STAT biochemical signaling pathway?
What are the latest WHO disease definitions for diagnosing myeloproliferative neoplasms?
